Evidence map›Paper›PMID 27141352›Full record

ArticleOncoimmunology2016

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.

Zuqiang Liu, Roshni Ravindranathan, Jun Li, Pawel Kalinski, Z Sheng Guo, David L Bartlett

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Natural and Engineered Cytokines as Cancer Therapeutics.Annual review of cancer biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zuqiang LiuThe University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Roshni RavindranathanThe University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Jun LiThe University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Pawel KalinskiThe University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA; Immunology, University of Pittsburgh, Pittsburgh, PA, USA; Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Z Sheng GuoThe University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
David L BartlettThe University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · USUPMC Hillman Cancer Center · US

Funding

Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-CelP01CA132714 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KALINSKI, PAWEL · 2009 to 2013
$6.8M
Improving Vaccinia for Peritoneal Tumors: Enhanced Distribution & Immune EvasionR01CA155925 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BARTLETT, DAVID L · 2011 to 2015
$1.5M
NCI NIH HHS P01 CA132714NCI NIH HHS R01 CA155925
6 · The paper itself

Abstract

We have armed a tumor-selective oncolytic vaccinia virus (vvDD) with the chemokine (CK) CXCL11, in order to enhance its ability to attract CXCR3

Indexed as

Antitumor immunityCD8+ T cellschemokineIFNγoncolytic virustherapeutic efficacytumor microenvironment

Identifiers

PMID27141352
PMCPMC4839379
OpenAlexW2289654340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.